Skip to main
PRLD

Prelude Therapeutics (PRLD) Stock Forecast & Price Target

Prelude Therapeutics (PRLD) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Prelude Therapeutics is a precision oncology company that utilizes its platform to develop highly selective and differentiated small molecule medicines to address high unmet need in cancer therapy. The company has a strong pipeline, including clinical-stage assets targeting well-validated mechanisms, as well as early-stage programs such as its KAT6A degrader (PRT13722) for HR+/HER2- breast cancer. The company has also secured collaborations to help advance its programs, including an exclusive option for its JAK2V617F inhibitor program with Incyte Corporation. Financially, Prelude has a strong cash position and has raised additional capital, providing a solid runway to advance its programs. With a deep pipeline, emerging clinical validation, and strong partnerships, Prelude Therapeutics is well-positioned for multi-asset value creation and potential upside for investors.

Bears say

Prelude Therapeutics is facing a negative outlook due to the evolving landscape in precision oncology, with broad-spectrum kinase inhibitors being replaced by high-precision molecular targeting. The lack of selectivity in traditional inhibitors leads to dose-limiting toxicities, making precision targeting more desirable. Additionally, the company's patents for specific therapies may provide additional exclusivity and potential for partnerships, but it remains to be seen if these efforts will be successful.

Prelude Therapeutics (PRLD) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prelude Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prelude Therapeutics (PRLD) Forecast

Analysts have given Prelude Therapeutics (PRLD) a Buy based on their latest research and market trends.

According to 4 analysts, Prelude Therapeutics (PRLD) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prelude Therapeutics (PRLD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.